Literature DB >> 29382441

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

M Neil Reaume1, Naveen S Basappa2, Lori Wood3, Anil Kapoor4,5, Georg A Bjarnason6, Normand Blais7, Rodney H Breau8, Christina Canil1, Patrick Cheung9, Henry J Conter10, Sebastien J Hotte11, Claudio Jeldres12, Michael A S Jewett13, Pierre I Karakiewicz14, Christian Kollmannsberger15, Francois Patenaude16, Alan So17, Denis Soulières7, Peter Venner2, Phillippe Violette4, Pawel Zalewski18, Heather Chappell19, Scott A North2.   

Abstract

Entities:  

Year:  2017        PMID: 29382441      PMCID: PMC5963441          DOI: 10.5489/cuaj.4769

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  89 in total

1.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Authors:  Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

Review 3.  Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Authors:  Dae Y Kim; Jose A Karam; Christopher G Wood
Journal:  World J Urol       Date:  2014-04-18       Impact factor: 4.226

4.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

5.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

6.  Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.

Authors:  Michael R Abern; Emelian Scosyrev; Matvey Tsivian; Edward M Messing; Thomas J Polascik; Arkadiusz Z Dudek
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

7.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Authors:  Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri
Journal:  Eur Urol       Date:  2014-06-13       Impact factor: 20.096

8.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.

Authors:  Bradley C Leibovich; Ken-ryu Han; Matthew H T Bui; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie Belldegrun
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

9.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

10.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

View more
  2 in total

1.  Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Authors:  Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume
Journal:  Can Urol Assoc J       Date:  2019-10       Impact factor: 1.862

2.  A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.

Authors:  Florian Guisier; Stephanie Cousse; Mathilde Jeanvoine; Luc Thiberville; Mathieu Salaun
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.